Comparing the current results to its competitors, Nektar Therapeutics reported Revenue decrease in the 2 quarter 2026 year on year by -9.34 %, despite the revenue increase by the most of its competitors of 6.64 %, recorded in the same quarter.
Nektar Therapeutics, slower than the average decrease reported by the company's competitors of -66.48 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -66.48 %
Atea Pharmaceuticals Inc. is a biopharmaceutical company that focuses on developing antiviral therapeutics to combat infectious diseases. Their business model revolves around identifying and advancing novel drug candidates that target specific viral mechanisms and inhibit their replication. This includes conducting preclinical and clinical trials, engaging in strategic partnerships, and ultimately bringing effective antiviral treatments to market.
Belite Bio Inc's business model involves leveraging biotechnology to develop and commercialize innovative solutions for various industries. They focus on creating sustainable and environmentally friendly products by harnessing the power of natural biological processes.
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
AbbVie Inc operates primarily as a global biopharmaceutical company, focusing on the research, development, manufacturing, and commercialization of advanced therapies and medications in critical areas such as immunology, oncology, neuroscience, and virology. The company aims to improve patient outcomes and address unmet medical needs by leveraging its scientific expertise and capabilities while providing value to stakeholders in the healthcare industry.
Sources:
Nektar Therapeutics’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Nektar Therapeutics versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
